[Source: Rna Diagnostics press release] Toronto, Ont., Canada, Dec. 8, 2025 — A new study by scientists at the Institute of Cancer Research (Oslo University Hospital) and Rna Diagnostics, a clinical-stage molecular diagnostics company, supports the use of the RNA disruptive assay (RDA) to predict tumour response to chemotherapy in early-stage breast cancer patients.

The study found that high levels of tumour RNA disruption during neoadjuvant chemotherapy was associated with improved disease-free survival in patients with HER2-negative breast cancer using supervised analyses. The researchers also found that high tumour RNA disruption, measured using the RDA, appeared to be a better predictor of treatment outcome than the post-treatment pathologic complete response (pCR) rate or residual cancer burden (RCB) index.

“There is an urgent need for new tools to identify patients who are unlikely to respond well to a particular chemotherapy treatment,” said John Connolly, CEO of Rna Diagnostics. “While this study involved a relatively small cohort of patients, the results indicate, that if the same result could be obtained early during treatment, RDA may be particularly useful for response-guided neoadjuvant chemotherapy. This would allow clinicians to recommend, early on, alternate treatments that may help to achieve a better outcome.”

Adventus conducted a market assessment for Rna Diagnostics in 2010.

Read the full press release here.